Burden of disease from cryptosporidiosis.
OBJECTIVE
The global significance of cryptosporidiosis is widespread and far-reaching. In this review, we present recent data about strain diversity and the burden of disease, along with developments in therapeutic and preventive strategies.


RESULTS
Cryptosporidium is an emerging pathogen that disproportionately affects children in developing countries and immunocompromised individuals. Without a diagnostic tool amenable for use in developing countries, the burden of infection and its relationship to growth faltering, malnutrition, and diarrheal mortality remain underappreciated. Disease incidence is also increasing in industrialized countries largely as a result of outbreaks in recreational water facilities. Advances in molecular methods, including subtyping analysis, have yielded new insights into the epidemiology of cryptosporidiosis. However, without practical point-of-care diagnostics, an effective treatment for immunocompromised patients, and a promising vaccine candidate, the ability to reduce the burden of disease in the near future is limited. This is compounded by inadequate coverage with antiretroviral therapy in developing countries, the only current means of managing HIV-infected patients with cryptosporidiosis.


CONCLUSIONS
Cryptosporidiosis is one of the most important diarrheal pathogens affecting people worldwide. Effective methods to control and treat cryptosporidiosis among high-risk groups present an ongoing problem in need of attention.
Division of Infectious Diseases and Tropical Pediatrics, Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Debbie-Ann T
DA
Shirley
Shannon N
SN
Moonah
Karen L
KL
Kotloff
D000953:Antigens, Protozoan / Q000032:analysis; D000977:Antiparasitic Agents / Q000627:therapeutic use; D017281:Cost of Illness; D003457:Cryptosporidiosis / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D003458:Cryptosporidium / Q000302:isolation & purification; D019049:Developed Countries; D003906:Developing Countries; D014943:Global Health; D006801:Humans
D000953:Antigens, Protozoan; D000977:Antiparasitic Agents